Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China · Delayed Price · Currency is CNY 26.53
-0.40 (-1.49%)
Feb 13, 2026, 3:00 PM CST
Aurisco Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 424.54 | 354.79 | 289.42 | 210.96 | 168.71 | 157.23 |
Depreciation & Amortization | 87.01 | 87.01 | 79.11 | 69.24 | 54.77 | 32.02 |
Other Amortization | 3.2 | 3.2 | 2.54 | 1.55 | - | - |
Loss (Gain) From Sale of Assets | 0.41 | 0.41 | 1.53 | 1.5 | 0.4 | 0.26 |
Asset Writedown & Restructuring Costs | 0.17 | 0.17 | - | - | - | 0.05 |
Loss (Gain) From Sale of Investments | -5.62 | -5.62 | -31.72 | 1.19 | -0.68 | -2.36 |
Provision & Write-off of Bad Debts | 3.55 | 3.55 | 4.18 | 4.19 | -0.09 | 0.74 |
Other Operating Activities | 0.64 | 20.4 | 6 | 3.89 | 2.33 | 8.6 |
Change in Accounts Receivable | -107.13 | -107.13 | -98.18 | -84.83 | 11.29 | -20.72 |
Change in Inventory | -201.43 | -201.43 | -72.52 | -125.97 | -89.01 | 1.83 |
Change in Accounts Payable | 161.15 | 161.15 | 174.55 | 70.56 | 55.41 | 30.65 |
Change in Other Net Operating Assets | 17.59 | 17.59 | 34.28 | 17.98 | 1 | 2.53 |
Operating Cash Flow | 382.39 | 332.41 | 385.61 | 166.41 | 201.57 | 214.48 |
Operating Cash Flow Growth | -3.97% | -13.80% | 131.72% | -17.44% | -6.02% | 19.22% |
Capital Expenditures | -343.54 | -540.28 | -305.48 | -216.23 | -250.61 | -158.8 |
Sale of Property, Plant & Equipment | 1.23 | 1.28 | 0.52 | 0.63 | 0.6 | 0.82 |
Cash Acquisitions | 201 | - | - | - | - | - |
Divestitures | - | - | 61.09 | - | - | - |
Investment in Securities | -260.15 | -191.34 | -121.44 | -41.44 | -15 | - |
Other Investing Activities | -100.03 | 3.56 | 0.03 | 0.25 | 2.68 | 0.97 |
Investing Cash Flow | -501.49 | -726.77 | -365.27 | -256.79 | -262.34 | -157.01 |
Long-Term Debt Issued | - | 986.04 | 135.79 | 37.12 | - | - |
Total Debt Issued | 186.98 | 986.04 | 135.79 | 37.12 | - | - |
Long-Term Debt Repaid | - | -153.64 | -71.87 | -5.94 | -4.37 | - |
Total Debt Repaid | -88.55 | -153.64 | -71.87 | -5.94 | -4.37 | - |
Net Debt Issued (Repaid) | 98.43 | 832.4 | 63.92 | 31.18 | -4.37 | - |
Issuance of Common Stock | - | - | - | 57.15 | - | 312.28 |
Common Dividends Paid | -126.72 | -94.82 | -67 | -52.34 | -48.12 | -36 |
Other Financing Activities | -22.37 | -3.22 | 52.1 | -50.9 | - | -29.34 |
Financing Cash Flow | -138.13 | 734.37 | 49.02 | -14.91 | -52.49 | 246.94 |
Foreign Exchange Rate Adjustments | 13.38 | 14.02 | 6.11 | 3.5 | -3.82 | -6.29 |
Net Cash Flow | -243.85 | 354.02 | 75.47 | -101.79 | -117.08 | 298.12 |
Free Cash Flow | 38.85 | -207.87 | 80.13 | -49.82 | -49.04 | 55.68 |
Free Cash Flow Growth | - | - | - | - | - | -48.17% |
Free Cash Flow Margin | 2.39% | -14.09% | 6.35% | -4.94% | -6.11% | 7.72% |
Free Cash Flow Per Share | 0.10 | -0.52 | 0.20 | -0.12 | -0.12 | 0.15 |
Cash Income Tax Paid | 20.35 | -12.74 | -18.15 | -35.73 | -27.6 | -9.63 |
Levered Free Cash Flow | -96.46 | -303.79 | 36.02 | -102.36 | -116.14 | 4.25 |
Unlevered Free Cash Flow | -74.52 | -293.93 | 37.73 | -101.73 | -115.74 | 4.25 |
Change in Working Capital | -131.5 | -131.5 | 34.55 | -126.11 | -23.88 | 17.93 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.